To evaluate the Safety and efficacy of two Unani formulations in the treatment of Leucorrhoea

Clinical Validation of Unani Pharmacopoeial formulation Kushta Khubs ul Hadeed and Habb e Marwareed in Sailan-ur-Reham(Leucorrhoea)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/02/005562

Enrollment

300

Registered

2015-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Sailan-ur-Reham(Leucorrhoea) Health Condition 2: A599- Trichomoniasis, unspecified Health Condition 3: A599- Trichomoniasis, unspecified

Interventions

Intervention1: Qurs e Kushta Khabs al-Hadeed: 1Tab (100 mg) Twice Daily Take after meals with water for 4 weeks Intervention2: Habb e Marwareed: Orally 1 Tab (250 mg) Twice Daily Take after meals with

Eligibility

Inclusion criteria

Inclusion criteria: • Female patients in the age group of 13-45 years. • Patients having excessive white discharge with or without any of the following associated symptoms ï?§ Backache ï?§ General Weakness ï?§ Anaemia

Exclusion criteria

Exclusion criteria: • Patients having acute/acute on chronic/Chronic PIDs as per Hegards Criteria (Annexure-IV) • Patients on long-term medications. • Patients on Oral Contraceptives/IUDs. • Patients taking hormonal therapy. • Any abnormal condition on p/s Examination. • Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptomsTimepoint: 4 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026